nsaid-safety

name	nsaid-safety
description	NSAID comparison (meloxicam, carprofen, deracoxib, firocoxib, robenacoxib), species-specific dosing, GI ulceration risk factors, renal monitoring protocols, corticosteroid washout requirements, COX-1 vs. COX-2 selectivity.

NSAID Safety

Overview

Evidence-based NSAID selection, dosing by species, contraindication recognition, and safety monitoring protocols. Includes COX-1 vs. COX-2 selectivity comparison, renal/GI risk stratification, and drug interaction management.

When to Use

• User prescribes NSAID or assesses drug safety for concurrent NSAID use
• User needs NSAID selection, dosing verification, or renal/GI monitoring plan
• Keywords: NSAID, meloxicam, carprofen, deracoxib, firocoxib, robenacoxib, GI ulcer, renal, COX, anti-inflammatory, contraindication, drug interaction

NSAID Comparison Table

Drug	Species	Dose	Route	Frequency	COX Selectivity	Comments
Meloxicam	Dog	0.1-0.2 mg/kg	PO/IV/SC	Daily	COX-2 preferential	Longer half-life (12-18h); IV/SC option; first-line many practices
	Cat	0.1 mg/kg	PO/SC/IV	Daily	COX-2 preferential	CONTROVERSIAL dosing: 0.3-0.5 mg/kg q48h alternative; GI risk lower than dogs at low dose; renal monitoring mandatory
	Rabbit	0.6-1 mg/kg	PO/SC	BID	COX-2 preferential	Limited data; anecdotal use; monitor renal/GI closely
Carprofen	Dog	2-4 mg/kg	PO/IV	BID-TID	COX-2 preferential (mild)	Rapid GI absorption; shorter half-life (8 hours); hepatotoxicity rare but reported
	Cat	1-2 mg/kg	PO/IV	BID	COX-2 preferential (mild)	Limited feline data; less commonly used in cats; GI ulceration risk higher than meloxicam
Deracoxib	Dog	1-2 mg/kg	PO	Daily	COX-2 selective	Food-dependent absorption (give with food); 5-7 day max acute, 30 days chronic (FDA restriction)
Firocoxib	Dog	5 mg/kg	PO	Daily	COX-2 highly selective	Equine label (5 mg/kg); less GI ulceration than carprofen; excellent for orthopedic pain; expensive
	Horse	0.1 mg/kg IV/5 mg/kg PO	PO/IV	Daily	COX-2 highly selective	Superior to phenylbutazone in some studies; longer plasma half-life
Robenacoxib	Dog/Cat	1-2 mg/kg	SC/IV	Daily × 4-10 days	COX-2 selective	Short-term use primarily; less renal effects at short durations; expensive; limited US availability

COX-1 vs. COX-2 Selectivity

COX-1 Functions: Gastric mucosal protection (prostaglandins), platelet aggregation, renal hemodynamics, tissue homeostasis

• Inhibition consequence: GI ulceration, platelet dysfunction, renal perfusion reduction

COX-2 Functions: Inflammation, fever, pain; also renal and gastric roles in chronic settings

• Selectivity advantage: Lower GI ulceration risk; some renal protective effects at lower doses

Clinical Implication: COX-2 selective agents (meloxicam, firocoxib, deracoxib, robenacoxib) safer GI profiles than less-selective agents (carprofen) in short-term use; long-term use blunts selectivity advantage

GI Ulceration Risk Factors

Intrinsic Risk (patient factors):

• Age (geriatric >7 years; puppies/kittens immature mucosa)
• Concurrent disease (inflammatory bowel disease, gastric ulcer history, neoplasia)
• Hepatic/renal disease (reduced clearance, decreased perfusion)
• Hypoproteinemia (<5.0 g/dL; reduced gastric mucosa protection)
• Dehydration (reduced gastric blood flow)
• NSAIDs increase risk 4-6× in dogs; cats lower baseline risk but elevation if predisposed

Extrinsic Risk (drug factors):

• High NSAID dose
• Prolonged duration (risk increases after 2-4 weeks)
• Concurrent corticosteroid use (synergistic ulceration risk; contraindicated)
• Concurrent anticoagulant (inhibited platelet aggregation)
• Multiple NSAIDs (avoid combining even "safer" pairs)

Gastroduodenal Complications:

• Grade 1: Gastric mucosal erythema, no erosion; asymptomatic
• Grade 2: Erosions <3 mm; vomiting possible
• Grade 3-4: Ulcers >3 mm, perforation risk; hematemesis, melena, severe pain

Renal Monitoring Protocol

Baseline Assessment (before NSAID initiation):

• Serum creatinine, BUN, urine specific gravity (USG)
• Contraindicate NSAID if: Cr >1.8 mg/dL (dogs), >1.6 mg/dL (cats); pre-existing renal disease; dehydration present

During Therapy:

• Recheck BUN/creatinine at 7-10 days if new NSAID (acute phase kidney injury risk peaks early)
• Repeat at 2-4 weeks if continuing >2 weeks duration
• For chronic NSAIDs (months+): Check q3-6 months

Renal NSAID Mechanism:

• Decrease renal perfusion (COX-2 inhibition reduces renal vasodilation)
• Acute kidney injury risk in hypovolemic/dehydrated states
• Chronic risk: Progressive glomerulosclerosis with prolonged high-dose use

Discontinuation Indications:

• Creatinine increase >0.5 mg/dL from baseline
• BUN >40 mg/dL without other explanation
• Evidence of acute kidney injury (azotemia + clinical signs)
• Oliguria/polyuria development

Species-Specific Dosing and Considerations

Dogs

• Standard dose: Meloxicam 0.1-0.2 mg/kg daily; carprofen 2-4 mg/kg BID
• Geriatric/renal disease: Reduce to minimum effective dose; meloxicam 0.1 mg/kg daily preferred (less renal impact)
• Post-operative: Start pre-operatively (pre-emptive analgesia); continue 5-7 days minimum
• Chronic orthopedic disease: Long-term meloxicam acceptable with monitoring; consider adjuvant agents (gabapentin, joint supplements) to minimize NSAID requirements

Cats

• Meloxicam controversy: AAHA (2017) recommends 0.1 mg/kg daily (same as dogs); some practitioners prefer 0.3-0.5 mg/kg q48h
  • Rationale: Feline renal physiology; lower baseline GI risk; extrarenal NSAID metabolism; palatability of sustained dosing
  • Conservative approach: 0.1 mg/kg daily with renal monitoring remains safest evidence-based recommendation
• GI risk: Cats more sensitive to severe GI ulceration than dogs despite lower overall baseline
• Renal monitoring: Mandatory (USG, BUN, creatinine baseline and q2-4 weeks)
• Chronic use: Short-term (acute pain, <2 weeks) preferred; long-term requires strong indication and close monitoring

Rabbits/Small Mammals

• Meloxicam: 0.6-1 mg/kg PO/SC BID common dosing (limited species-specific data)
• GI stasis risk: Meloxicam may reduce appetite/motility; ensure adequate hydration and hay intake
• Carprofen: Anecdotal use; minimal data; generally avoided
• Monitoring: Renal monitoring less standardized; assess appetite, fecal output, hydration

Horses

• Firocoxib: 5 mg/kg daily PO (approved label); superior to phenylbutazone (PBZ, older standard) in some pain models
• Phenylbutazone: Traditional (4.4 mg/kg daily max); longer-term GI ulceration risk; now second-line
• Monitoring: Renal dysfunction less common in horses; GI ulceration still risk
• Maximum duration: 30 days typically recommended (extended use controversial)

Corticosteroid + NSAID Interaction

Mechanism: Corticosteroids inhibit phospholipase A2 (blocks arachidonic acid release); NSAIDs inhibit COX; combined blockade → synergistic GI ulceration

Contraindication: Absolute: Do NOT combine systemic corticosteroid + NSAID concurrently

• Washout period: Discontinue corticosteroid ≥1 week before initiating NSAID OR discontinue NSAID ≥1 week before corticosteroid

Exception: Topical corticosteroids (ophthalmic, dermal) + systemic NSAID generally safe (minimal systemic absorption)

Alternative: Use NSAID + adjuvant analgesic (gabapentin, tramadol) instead of corticosteroid if possible

Drug Interactions and Contraindications

NSAIDs + Anticoagulants (warfarin, apixaban): Increased bleeding risk; avoid if possible; if necessary, use lowest NSAID dose, monitor INR closely NSAIDs + ACE Inhibitors (enalapril, lisinopril): Combined renal perfusion reduction; acceptable in euvolemic patients; contraindicated if dehydrated NSAIDs + Diuretics: Reduced renal perfusion; monitor renal function closely; ensure adequate hydration NSAIDs + Methotrexate: Reduced MTX clearance; potential toxicity; monitor closely

Absolute Contraindications:

• Acute/chronic kidney disease (Cr >1.8 dogs, >1.6 cats without specialist guidance)
• Severe hepatic disease
• Active GI ulceration (confirmed or high suspicion)
• Platelet dysfunction disorders
• Concurrent corticosteroid (system non-topical)
• Hypersensitivity/allergy history

GI Protection Strategies

H2 Blockers (famotidine 0.5-1 mg/kg q12h):

• Reduces gastric acid; modest ulceration prevention
• Minimal evidence for routine prophylaxis in short-term NSAID use
• Consider if: Geriatric, pre-existing GI disease, high-risk NSAID choice

Proton Pump Inhibitors (omeprazole 0.5-1 mg/kg q24h):

• Superior acid suppression to H2 blockers
• Limited evidence for routine prophylaxis short-term
• Consider if: High-risk patient, previous NSAID intolerance, chronic NSAID use

Misoprostol (2-5 mcg/kg q6-8h): Prostaglandin analog; promotes gastric mucosa protection

• Reduced diarrhea (side effect) in cats; avoid if GI dysmotility risk
• Limited practical use due to dosing frequency

Evidence: Routine GI protection not recommended for short-term (<2 weeks) NSAID use in low-risk patients; consider for high-risk or chronic use

Monitoring and Patient Selection Workflow

1. Assess renal function baseline: Serum creatinine, BUN, USG; exclude if abnormal
2. Assess GI risk: History of ulceration, concurrent medications, age, dehydration status
3. Select appropriate NSAID: COX-2 selective (meloxicam, firocoxib) preferred over less-selective agents; meloxicam for cats with renal monitoring
4. Verify no corticosteroid within 1 week: Washout period essential
5. Establish monitoring plan: Recheck creatinine/BUN at 7-10 days if new prescription; q2-4 weeks if chronic; assess appetite/vomiting at each visit
6. Educate owner: Signs of GI ulceration (vomiting, melena, anorexia); signs of renal disease (polyuria, polydipsia, lethargy); importance of monitoring

Limitations

• Baseline renal assessment: Many animals have subclinical renal disease (eGFR reduced despite normal creatinine); urine protein assessment (UP:C) not routine in screening
• NSAID selectivity: Clinical significance of COX-1 vs. COX-2 selectivity debated; all NSAIDs carry GI/renal risk at higher doses or longer duration
• Feline meloxicam dosing: Significant controversy; "safe" dose remains undefined; individual variation large
• GI protection efficacy: Limited high-quality evidence for routine prophylaxis; many protection strategies add cost without proven benefit in short-term use
• Chronic NSAID use: Long-term safety data limited; adjuvant agents (gabapentin, joint supplements) may reduce NSAID requirements but evidence variable
• Referral: Complex polypharmacy, unexplained renal elevation during NSAID therapy, or refractory pain → internist/pain specialist consideration